Johnson & Johnson Q2 earnings beat forecasts, lifts outlook

Johnson & Johnson reported second-quarter sales of $25.31 billion on Wednesday, July 15, 2026, exceeding analyst expectations and raising its full-year financial outlook. The healthcare giant's revenue grew 6.6% from the same period last year, driven by strong performance in its pharmaceutical division.

Adjusted earnings per share were $2.90, a 4.7% year-over-year increase and above the consensus estimate of $2.85. The company's Innovative Medicine segment, which houses its pharmaceutical products, generated $16.38 billion in sales, a 7.8% increase. Key growth drivers included the cancer treatments Darzalex and Carvykti, the immunology drug Tremfya, and neuroscience products Spravato and Caplyta. Tremfya sales surged 72.5% to $2 billion, while Darzalex revenue reached $4.2 billion. These gains were partially offset by declining sales of older products, including Stelara, which has faced biosimilar competition since losing patent protection.

The company's MedTech unit recorded $8.93 billion in quarterly sales, a 4.5% increase, though this figure slightly missed analyst expectations. Chief Financial Officer Joseph Wolk noted that sales from the acquired heart pump company Abiomed...